Payment overview · 2025
General Payments
$79.58
3 reported records · 3 companies
Healthcare provider profile · identity verified
Sion Kim, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH LAS VEGAS, NV · NPI 1871013631
Verified facts
What the public records show
CMS Open Payments records show Sion Kim, MD received $79.58 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.24 | 40.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $24.71 | 31.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.63 | 28.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.58 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1095 | 367 |
| Levothyroxine Sodium | Levothyroxine Sodium | 606 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 575 | 204 |
| Losartan Potassium | Losartan Potassium | 565 | 191 |
| Lisinopril | Lisinopril | 441 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 297 | 116 |
| Metformin Hcl | Metformin Hcl | 296 | 110 |
| Omeprazole | Omeprazole | 239 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 115 |
| Gabapentin | Gabapentin | 206 | 83 |
| Prednisone | Prednisone | 203 | 151 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 199 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 73 |
| Ozempic | Semaglutide | 196 | 56 |
| Metformin Hcl Er | Metformin Hcl | 193 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 72 |
| Simvastatin | Simvastatin | 184 | 58 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 173 | 91 |
| Alendronate Sodium | Alendronate Sodium | 169 | 58 |
| Allopurinol | Allopurinol | 167 | 59 |
| Azithromycin | Azithromycin | 164 | 138 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 53 |
| Trazodone Hcl | Trazodone Hcl | 147 | 46 |
| Potassium Chloride | Potassium Chloride | 143 | 56 |
| Methocarbamol | Methocarbamol | 131 | 81 |
| Eliquis | Apixaban | 128 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 43 |
| Mounjaro | Tirzepatide | 119 | 30 |
| Montelukast Sodium | Montelukast Sodium | 115 | 45 |
| Carvedilol | Carvedilol | 113 | 40 |
| Famotidine | Famotidine | 111 | 45 |
| Glipizide Er | Glipizide | 111 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 51 |
| Sertraline Hcl | Sertraline Hcl | 98 | 32 |
| Jardiance | Empagliflozin | 90 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 78 |
| Furosemide | Furosemide | 84 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 26 |
| Sildenafil Citrate | Sildenafil Citrate | 78 | 20 |
| Tramadol Hcl | Tramadol Hcl | 78 | 20 |
| Ibuprofen | Ibuprofen | 74 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 73 | 35 |
| Atenolol | Atenolol | 69 | 24 |
| Nystatin | Nystatin | 69 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 23 |
| Lovastatin | Lovastatin | 66 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 22 |
| Meloxicam | Meloxicam | 63 | 28 |
| Mupirocin | Mupirocin | 63 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 24 |
| Alprazolam | Alprazolam | 60 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 21 |
| Mirtazapine | Mirtazapine | 57 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 20 |
| Benazepril Hcl | Benazepril Hcl | 55 | 19 |
| Temazepam | Temazepam | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 17 |
| Farxiga | Dapagliflozin Propanediol | 50 | 18 |
| Glipizide | Glipizide | 50 | 15 |
| Ezetimibe | Ezetimibe | 49 | 21 |
| Valsartan | Valsartan | 49 | 20 |
| Finasteride | Finasteride | 46 | 17 |
| Acyclovir | Acyclovir | 45 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 14 |
| Meclizine Hcl | Meclizine Hcl | 38 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Baclofen | Baclofen | 37 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 35 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 14 |
| Rybelsus | Semaglutide | 34 | 11 |
| Memantine Hcl | Memantine Hcl | 33 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 13 |
| Prolia | Denosumab | 33 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 13 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 12 |
| Ibu | Ibuprofen | 29 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Spironolactone | Spironolactone | 27 | 13 |
| Fluconazole | Fluconazole | 26 | 18 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | 11 |
| Lactulose | Lactulose | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | 14 |
| Naproxen | Naproxen | 24 | 11 |
| Ramipril | Ramipril | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.58 · 3 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, FARXIGA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error